000			03682cam a2200637 i 4500
001			ocn915775232
003			OCoLC
005			20171024102454.0
006			m o d
007			cr |||||||||||
008			150803s2015 nju o 001 0 eng
010			_a 2015030480
020			_a9781118914342 (epub)
020			_a1118914341 (epub)
020			_a9781118819449 (pdf)
020			_a1118819446 (pdf)
020			_z9781118679678 (cloth)
020			_a9781118819586
020			_a1118819586
020			_a1118679679 (cloth)
020			_a9781118679678 (cloth)
029	1		_aDEBBG _bBV043399087
029	1		_aDEBSZ _b480371997
035			_a(OCoLC)915775232
040			_aDLC _beng _erda _cDLC _dOCLCF _dN$T _dDG1 _dYDXCP _dCOO _dIDEBK _dCDX _dEBLCP _dRECBK _dDEBBG _dKSU _dDEBSZ
042			_apcc
049			_aMAIN
050	0	0	_aHD9665.5
072		7	_aMED _x071000 _2bisacsh
082	0	0	_a615.1068/5 _223
100	1		_aAlex, Alexander A., _eeditor.
245	1	0	_aAttrition in the pharmaceutical industry : reasons, implications, and pathways forward / _cedited by Alexander A. Alex, C. John Harris, Dennis A. Smith. _h[electronic resource]
264		1	_aHoboken, New Jersey : _bJohn Wiley & Sons, _c2015.
300			_a1 online resource.
336			_atext _2rdacontent
337			_acomputer _2rdamedia
338			_aonline resource _2rdacarrier
500			_aIncludes index.
505	0		_aAttrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.
588			_aDescription based on print version record and CIP data provided by publisher.
650		0	_aPharmaceutical industry _xManagement.
650		0	_aPharmaceutical industry _xCapital productivity.
650		0	_aIndustrial efficiency.
650		0	_aDrug development.
650		7	_aDrug development. _2fast _0(OCoLC)fst00898670
650		7	_aIndustrial efficiency. _2fast _0(OCoLC)fst00970970
650		7	_aPharmaceutical industry _xCapital productivity. _2fast _0(OCoLC)fst01767658
650		7	_aPharmaceutical industry _xManagement. _2fast _0(OCoLC)fst01060159
650		7	_aMEDICAL / Pharmacology _2bisacsh
655		4	_aElectronic books.
700	1		_aHarris, C. John, _eeditor.
700	1		_aSmith, Dennis A., _eeditor.
776	0	8	_iPrint version: _aAlex, Alexander A., editor. _tAttrition in the pharmaceutical industry _dHoboken, New Jersey : John Wiley & Sons, 2015 _z9781118679678 _w(DLC) 2015024772
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118819586 _zWiley Online Library
942			_2ddc _cBK
999			_c208132 _d208132